Photo from Erika Hamilton/LinkedIn
Jan 14, 2024, 17:39
Erika Hamilton: Happy to share publication on updated monarchE data with adjuvant abemaciclib
Erika Hamilton , Chair of Executive Committee Breast and Breast Program lead at Sarah Cannon Research Institute, shared on LinkedIn:
“Happy to share publication on updated monarchE data with adjuvant abemaciclib. With 5 year follow-up, we see continued separation of curves after 2 year abema treatment period.
DFS benefit at 5 years is now 7.6% favoring abema.
Although OS not significant at this follow-up, control arm has double the amount of patients now living with metastatic breast cancer.
Encouraging to know that through clinical trial participation, so many women accessed this therapy years ahead of approval.“
Read Further.
Source: Erika Hamilton/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 31, 2025, 10:18
Mar 31, 2025, 10:01
Mar 31, 2025, 09:26
Mar 31, 2025, 08:53
Mar 31, 2025, 08:34
Mar 31, 2025, 08:32
Mar 31, 2025, 08:24